Drug Trial Radar · NCT01150344
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Last checked: Nov 20, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
317
Actual
Start
Jul 2010
Primary completion
Apr 2014
Study completion Nov 2015
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria. The aim of the study is to compare both tolerance and efficacy of Malarone® and Riamet® in the treatment of uncomplicated imported malaria and to determine clinical and parasitological predictive factors associated with a less effectiveness. It's a multicentric, randomised study in adults with uncomplicated malaria. Treatment will be administered for 3 days, and patients will be followed for 28 days, to evaluate the therapeutic evolution. 640 patients will be included among 15 centres.
Conditions
- Malaria
Interventions
Malarone (atovaquone + proguanil combination)Drug
4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
RIAMET (artemether + LUMEFANTRIN combination)Drug
4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of cases where a second line treatment is used for either intolerance or lack of effectivenessTime frame: within the 28 days after diagnosis of malaria
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Avicenne
Bobigny, Seine St Denis, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.